A randomised controlled clinical trial to evaluate the anti-osteolytic agent clodronate for the prevention of the development of bone metastases in patients with primary breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN83688026

Enrollment

1000

Registered

2006-02-01

Start date

1989-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Breast cancer

Interventions

Clodronate 1600 mg taken orally per day for two years

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Histologically or cytologically confirmed primary operable breast cancer with no evidence of metastases

Exclusion criteria

Exclusion criteria: 1. Significant renal, hepatic or non-malignant bone disease 2. Previous history of malignant disease 3. Prior bisphosphonate use

Design outcomes

Primary

Measure	Time frame
Time to first bone metastases over five-year study period	—

Secondary

Measure	Time frame
Survival	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 22, 2026